Table 1. KRasG12C switch-II pocket inhibitors.
| Compound name in publication | Numbering in this article | Chemical structure | PDB ID | Reference | Company/origin | Phase | ID |
| 2E07 | 1 |
|
— | Ostrem et al. (2013)22 | Shokat Laboratory | — | — |
| 6H05 | 2 |
|
— | Ostrem et al. (2013)22 | Shokat Laboratory | — | — |
| Compound 6 | 3 |
|
4luc | Ostrem et al. (2013)22 | Shokat Laboratory | — | — |
| Compound 9 | 4 |
|
4lyh | Ostrem et al. (2013)22 | Shokat Laboratory | — | — |
| 4lyj | |||||||
| Compound 12 | 5 |
|
— | Ostrem et al. (2013)22 | Shokat Laboratory | — | — |
| ARS-107 | 6 |
|
6b0v | Patricelli et al. (2016)23 | Wellspring Bioscience | — | — |
| ARS-853 | 7 |
|
5f2e | Patricelli et al. (2016)23 | Wellspring Bioscience | — | — |
| ARS-1620 | 8 |
|
5v9u | Janes et al. (2018)24 | Wellspring Bioscience | — | — |
| Indole lead 1 | 9 |
|
6p8z | Shin et al. (2019)27 | Amgen | — | — |
| AMG 510 | 10 |
|
6oim | Canon et al. (2019)29 | Amgen | I/II | NCT03600883 |
| NCT04185883 | |||||||
| Compound 4 | 11 |
|
6n2j | Fell et al. (2018)36 | Array BioPharma | — | — |
| Mirati Therapeutics | |||||||
| Compound 13 | 12 |
|
— | Fell et al. (2018)36 | Array BioPharma | — | — |
| Mirati Therapeutics | |||||||
| MRTX849 | 13 |
|
6ut0 | Hallin et al. (2019)37 | Mirati Therapeutics | I/II | NCT03785249 |
| Fell et al. (2020)38 | |||||||
| JNJ-74699157 (ARS-3248) | 14 | — | — | — | J&J Wellspring Bioscience | I | NCT04006301 |